Apellis Pharmaceuticals’ (APLS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a report released on Thursday,Benzinga reports. The brokerage currently has a $57.00 price target on the stock.

Other analysts have also recently issued research reports about the stock. Mizuho reduced their price objective on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a research note on Thursday, October 24th. Morgan Stanley initiated coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 price target for the company. Evercore ISI upgraded Apellis Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, October 31st. Needham & Company LLC reduced their target price on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Finally, Citigroup lowered their price target on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Eight analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $46.71.

Apellis Pharmaceuticals Stock Down 3.7 %

NASDAQ:APLS opened at $27.46 on Thursday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals has a one year low of $24.34 and a one year high of $71.90. The firm’s 50 day simple moving average is $31.45 and its 200 day simple moving average is $32.30. The company has a market cap of $3.42 billion, a PE ratio of -13.53 and a beta of 0.96.

Insider Transactions at Apellis Pharmaceuticals

In related news, insider Caroline Baumal sold 2,816 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $33.81, for a total value of $95,208.96. Following the transaction, the insider now directly owns 55,560 shares in the company, valued at $1,878,483.60. This trade represents a 4.82 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Timothy Eugene Sullivan sold 2,170 shares of the business’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $28.70, for a total transaction of $62,279.00. Following the sale, the chief financial officer now owns 88,100 shares of the company’s stock, valued at $2,528,470. This trade represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 60,365 shares of company stock valued at $1,810,479 in the last 90 days. 6.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several large investors have recently added to or reduced their stakes in APLS. EverSource Wealth Advisors LLC increased its holdings in Apellis Pharmaceuticals by 2,707.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock worth $25,000 after purchasing an additional 758 shares in the last quarter. Wolverine Asset Management LLC purchased a new position in shares of Apellis Pharmaceuticals during the third quarter valued at approximately $27,000. True Wealth Design LLC bought a new stake in Apellis Pharmaceuticals during the third quarter worth $27,000. Signaturefd LLC raised its position in Apellis Pharmaceuticals by 357.2% in the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after buying an additional 918 shares during the last quarter. Finally, Capital Performance Advisors LLP bought a new position in Apellis Pharmaceuticals during the 3rd quarter valued at $56,000. Institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).